Satellos Bioscience, Inc.
This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD including those who previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of orally administered SAT-3247 60 mg in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months (Group A) or 12 months (Group B), respectively. The study will enroll up to 30 participants, including up to 5 who previously participated in the SAT-3247-CL-101 study.
Inclusion Criteria: * Previously participated in the SAT-3247-CL-101 parent clinical trials (Group A only). * No previous treatment with SAT-3247 (Group B only) * Continued status of stable glucocorticosteroid dose or no glucocorticosteroid dose for the duration of the trial. * Continued stable doses of prescription medicines (excluding glucocorticosteroids) and over-the-counter medicines and/or herbal supplements for supportive care for the duration of the trial. * Previously received delandistrogene moxeparvovec (brand name Elevidys) either in a prior clinical trial or in the commercial set…
AAK1 inhibitor